TRAILBody™ Program
Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Key Facts
About TRIO Pharmaceuticals
TRIO Pharmaceuticals is a preclinical-stage biotech pioneering a novel class of dual-targeting antibodies designed to kill cancer cells more precisely while simultaneously overcoming the immunosuppressive tumor microenvironment. Its two core platforms, TIE-ADC™ and TRAILBody™, address key limitations of current therapies—toxicity and immune evasion—across a pipeline focused on AML/MDS, ovarian/endometrial cancer, TNBC, and NSCLC. Founded by experienced drug developers with prior successful exits, the company is positioned to advance its candidates toward clinical development, targeting areas of high unmet medical need.
View full company profileAbout TRIO Pharmaceuticals
TRIO Pharmaceuticals is a preclinical-stage biotech pioneering a novel class of dual-targeting antibodies designed to kill cancer cells more precisely while simultaneously overcoming the immunosuppressive tumor microenvironment. Its two core platforms, TIE-ADC™ and TRAILBody™, address key limitations of current therapies—toxicity and immune evasion—across a pipeline focused on AML/MDS, ovarian/endometrial cancer, TNBC, and NSCLC. Founded by experienced drug developers with prior successful exits, the company is positioned to advance its candidates toward clinical development, targeting areas of high unmet medical need.
View full company profile